Sheng Ruizehua Completes Tens of Millions RMB Angel Financing Led by Kaitai Capital

VCBeat has learned that recently,Shengruizehua Pharmaceutical Technology (Suzhou) Co., Ltd.(hereinafter referred to as "Sheng Rui Ze Hua”) announced the completion of its angel round financing, amounting to tens of millions of yuan, led byExclusively Invested by Kaitai Capital. The funds raised in this offering will be primarily used to support the CompanyDevelopment of Existing Product Pipeline and Platformization of Proprietary Drug Development Technologiesand the correspondingEstablishment of Intellectual Property Protection, laying a solid and robust foundation for the company's future development.

Shengruizehua was established in 2022 and is positioned as aSmall Molecule Drug DevelopmentandPlatformization of Proprietary Drug Development Technologywith the goal of becoming an innovative drug R&D company equipped with rapid drug development capabilities. The founding team is led by senior scientists from renowned U.S. universities and pharmaceutical companies, bringing extensive experience and unique insights in precision medicine and innovative drug development.

The company will leverage its unique innovative drug development platform built by its team to accelerate the early discovery and R&D of innovative drugs in China, particularlyEarly Screening of Molecular Glue Drugs. Building on this platform, the company has currently secured two mature products. In the near term, the company’s efforts will focus primarily on advancing the clinical development of its existing product pipeline and further refining the platform.

Dr. Deng Lisheng, Founder of Sheng Rui Ze HuaHe stated, “As the company’s founder, I am fully aware of the critical importance of selecting the right therapeutic area. We will continue to uphold our innovative platform and differentiated product concepts. In the early stage of development, the company plans to advance two candidate new drugs with differentiated characteristics and file Investigational New Drug (IND) applications for them. Meanwhile, we will build a rapid drug development platform with independent intellectual property rights, thereby accumulating strength for our subsequent R&D pipeline and long-term growth. Hangzhou Kaitai Capital Management Ltd. has demonstrated profound insights into the future development of the biopharmaceutical industry. We are honored that our R&D capabilities and growth potential have been recognized and supported by Kaitai Capital. This is deeply moving to me and my team, and it further strengthens our resolve to pursue relentless innovation.”

Huang Zehua, Partner at Kaitai Capital“It is widely acknowledged that the investment required for the R&D of innovative small-molecule drugs is substantial, yet timelines remain a formidable hurdle that such projects often struggle to overcome. Leveraging its proprietary drug development platform and compound library resources, Shengrui Zehua is well-positioned to address these bottlenecks by resolving common challenges in drug development, such as difficult progression and low efficiency, thereby enhancing controllability over both project advancement and investment risk. The two product pipelines developed by the Shengrui Zehua team using this platform technology demonstrate excellent druggability and broad application prospects. We are confident that, with the support of Hangzhou Kaitai Capital Management Ltd., Shengrui Zehua—backed by an outstanding team and independent intellectual property rights—will soon validate the value of its platform through its product pipelines, establish its brand, and benefit more patients.”

Kaitai Capital refines its industrial ecosystem investment, identifies enterprise value, and co-creates value.

Kaitai Capital remains steadfast in its focus on unmet clinical needs, strategically investing across the biopharmaceutical and life sciences ecosystem. In these fields, Kaitai Capital prioritizes platform technologies capable of transforming the current trajectory of biopharmaceutical development and driving breakthrough innovations. The firm seeks to apply these technologies to drug development for a wide range of indications, with portfolio companies addressing areas such as oncology, metabolic disorders, cardiovascular diseases, anti-infectives, autoimmune diseases, neuroscience, dermatology, and respiratory diseases, all aimed at addressing unmet medical needs. To date, Kaitai Capital has invested in more than 100 biopharmaceutical and life sciences companies both in China and abroad.

Kaitai Capital not only prioritizes the discovery of enterprise value but also places equal emphasis on providing portfolio companies with sustained capital support, resource integration, talent matchmaking, and other value-added post-investment services. Looking ahead, we will continue to leverage a global perspective, forward-looking industry research, and an industrial ecosystem investment philosophy to drive the development of the global innovative biopharmaceutical industry.